Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.33 |
| ▸ | FEN1 | P39748 | 3/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | HTR7 | P34969 | 2/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
| ▸ | UGCG | Q16739 | 1/20 | 0.30 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815094 | 0.88 | KDR (0.43) | CHEK1KDR | |
| SCHEMBL4813087 | 0.87 | CHEK1 (0.42) | CHEK1KDR | |
| SCHEMBL4813208 | 0.80 | CHEK1 (0.35) | CHEK1DGAT1 | |
| SCHEMBL4818711 | 0.72 | CHEK1 (0.39) | CHEK1KDR | |
| SCHEMBL4817945 | 0.71 | CHEK1 (0.49) | CHEK1 | |
| SCHEMBL4816587 | 0.71 | CHEK1 (0.48) | CHEK1KDR | |
| SCHEMBL4813668 | 0.70 | CHEK1 (0.39) | CHEK1ALOX5APFEN1 | |
| SCHEMBL4811592 | 0.70 | CHEK1 (0.36) | CHEK1DGAT1ALOX5APFEN1KDR | |
| SCHEMBL4806272 | 0.69 | CHEK1 (0.52) | CHEK1 | |
| SCHEMBL15312322 | 0.69 | DGAT1 (0.40) | CHEK1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | CHEK1 73/4885DGAT1 3033/4885ALOX5AP 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.